scholarly journals Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review

2012 ◽  
Vol 6 (2) ◽  
Author(s):  
Ettore De Berardinis ◽  
Gian Maria Busetto ◽  
Riccardo Giovannone ◽  
Gabriele Antonini ◽  
Mariarosaria Di Placido, ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Cell Cancer ◽  
Transitional Cell ◽  
Urothelial Cell Carcinoma ◽  
Benign Lesions ◽  
Transitional Cell Cancer ◽  
Nested Variant ◽  
Carcinoma Of The Bladder ◽  
Cystitis Cystica ◽  
Nephrogenic Metaplasia

Nested variant of urothelial cell carcinoma (NVUC) is a rare histological entity, with about 80 reported cases. It has a deceptively benign appearance with an aspect characterized by confluent small nest or urothelial’s cell tubules. This tumour often resembles inverted papilloma, von Brunn’s nests (VBNs), cystitis cystica, nephrogenic metaplasia and sometimes usual transitional cell cancer. It is very important to be able to distinguish between benign lesions and nested variant bladder cancer because, in spite of its bland morphology, there is evidence that it behaves aggressively.

Bacillus Calmette–Guérin (BCG) Immunotherapy for Recurrent Noninvasive Transitional Cell Carcinoma of the Bladder

2021 ◽  
pp. 135-140
Author(s):  
Vikram M. Narayan
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Grade ◽  
Bacillus Calmette Guerin ◽  
Urothelial Cell Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Disease Specific

This study summarizes the landmark study assessing the value of maintenance intravesical Bacillus Calmette Guerin (BCG) to reduce the risk for recurrence or progression of high-grade superficial or carcinoma in situ (CIS) transitional cell carcinoma of the bladder. The trial randomized patients with completely resected noninvasive urothelial cell carcinoma at high risk of recurrence to BCG induction alone versus BCG induction plus maintenance therapy in the form of six weekly treatments. The study found that maintenance BCG reduces disease-specific recurrence and may also reduce the rate of disease progression.

scholarly journals Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review

2012 ◽  
Vol 6 (2) ◽  
pp. 57-60 ◽  
Author(s):  
Ettore De Berardinis, ◽  
Gian Maria Busetto ◽  
Riccardo Giovannone ◽  
Gabriele Antonini ◽  
Mariarosaria Di Placido, ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Nested Variant ◽  
Carcinoma Of The Bladder

scholarly journals Conservative Management of Transitional Cell Carcinoma of the Kidney and Ureter

1995 ◽  
Vol 1 (3) ◽  
pp. 121-123 ◽  
Author(s):  
Gregory T. Bales ◽  
Edward S. Lyon ◽  
Glenn S. Gerber
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Cancer ◽  
Transitional Cell ◽  
Disease Recurrence ◽  
Upper Urinary Tract ◽  
Multiple Organ ◽  
Low Grade ◽  
Transitional Cell Cancer ◽  
Disease Free

We report six patients with upper tract transitional cell neoplasms who were treated by an endourologic approach. Two patients had undergone nephroureterectomy previously, whereas one patient had a single functioning kidney. Two patients were deemed candidates for endourologic procedures secondary to significant comorbid disease precluding major open surgery. The final patient had a low-grade distal ureteral lesion and desired a conservative approach.Of six patients, two were rendered tumor free without recurrence 48 months and 60 months after surgery. Two patients had multiple superficial recurrences managed endoscopically and are currently disease free after 12 and 48 months, respectively. One patient died from metastatic transitional cell cancer 18 months postoperatively whereas one died perioperatively secondary to bleeding and multiple organ failure.Of five patients who tolerated endoscopic therapy, four were disease free with a mean follow-up of 30 months. Endoscopic treatment of upper urinary tract transitional cell carcinoma is feasible, although the risk of disease recurrence and progression may be significant.

Percutaneous Bcg Treatment in Superficial Transitional Cell Cancer of the Upper Urinary Tract

1993 ◽  
Vol 60 (1) ◽  
pp. 34-36 ◽  
Author(s):  
P. Bassi ◽  
A. Tasca ◽  
F. Zattoni ◽  
A. Calabrò ◽  
G. Abatangelo ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Cancer ◽  
Transitional Cell ◽  
Upper Urinary Tract ◽  
Feasible Option ◽  
Transitional Cell Cancer ◽  
Disease Free

From January 1989 to September 1992, 5 patients (age 58–68 years) were treated with percutaneous Pasteur BCG for superficial transitional cell carcinoma of the upper urinary tract. In 4 cases BCG was prophylactic after endourological resection of the tumors. In one case of bilateral Tis of the upper urinary tract, BCG was administered for therapeutical purposes. Every patient received 375 mg Pasteur BCG in 250 ml saline, every 2 weeks for 6 consecutive weeks in 2 patients, 5 weeks in 1, and 4 in 2. No major complications were observed. After a median follow-up of 10.2 months, 4 patients are disease free, 1 patient underwent nephroureterectomy. Percutaneous BCG in upper tract superficial transitional cell cancer seems a feasible option in selected cases.

scholarly journals ANALYSIS OF THE EXPRESSION OF FAS/CD95 AND HSP70 IN LOW AND HIGH GRADE UROTHELIAL CELL CARCINOMA OF THE BLADDER

2017 ◽  
Vol 53 (4) ◽  
pp. 247
Author(s):  
Heryanto Heryanto ◽  
Etty Hary Kusumastuti ◽  
Anny Setijo Rahaju
Keyword(s):  
Cell Carcinoma ◽  
Transitional Cell ◽  
Urothelial Cell ◽  
Hsp70 Expression ◽  
Low Grade ◽  
High Grade ◽  
Urothelial Cell Carcinoma ◽  
Cross Sectional ◽  
Carcinoma Of The Bladder ◽  
Spearman Test

Urothelial Cell Carcinoma (UCC), also called transitional cell carcinoma of the bladder, is the most common malignancy in urinary tract. The prognosis of this disease is highly dependent on the histological grading at diagnosis. Fas/CD95 has a role in apoptotic process, whereas HSP70 has an antiapoptotic role. This study aimed to analyze the expression of Fas/CD95 and HSP70 in low grade and high grade urothelial cell carcinoma in the bladder. This was an analytic observational study with cross sectional approach. Population and sample were paraffin blocks of urothelial cell carcinoma in the Laboratory of Anatomic Pathology, Dr. Soetomo Hospital, Surabaya in the period of January 2011-December 2016. Each grading of urothelial cell carcinoma was randomly sampled. Immunohistochemystry with Fas/CD95 and HSP70 were performed. Expression of Fas/CD95 and HSP70 were assessed semiquantitatively. Expression of Fas/CD95 and HSP70  were analyzed using Mann-Whitney test and Spearman test. The results showed there was significant different in expression of Fas/CD95 and HSP70 in low and high grades in urothelial cell carcinoma. There was no significant correlation between the expression of Fas/CD95 and HSP70 in urothelial cell carcinoma.  As a conclusion, the role of CD95 and HSP70 expression can be useful as marker for the diagnosis, especially in the determination of the grade of differentiation.

969: Intravesical Antisense G3139 Efficacy in Transitional Cell Carcinoma of the Bladder

2004 ◽  
Vol 171 (4S) ◽  
pp. 257-257
Author(s):  
Sam B. Gray ◽  
Brian J. Duggan ◽  
Perry Maxwell ◽  
Ken Arthur ◽  
Neil Anderson ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Carcinoma Of The Bladder
Sign in / Sign up

Export Citation Format

Share Document